GSM is the medical term for the cluster of genital, sexual and urinary changes that come from declining estrogen and androgen levels in the tissues of the vagina, vulva, urethra and bladder.
Because those tissues are dense in hormone receptors, one hormonal shift produces dryness, irritation, pain with sex, urinary urgency, frequency and recurrent infections together, which is why they are treated as one syndrome rather than separate problems. It affects a very wide range of postmenopausal women, estimated at 27 percent to 84 percent depending on the study. Unlike hot flashes, GSM tends to be chronic and progressive, meaning it usually does not improve on its own without treatment. It is also widely underdiagnosed, in large part because most women never connect their symptoms to menopause in the first place.
The physiology and undertreatment numbers are not seriously disputed. Where real disagreement remains is how universal and how automatically treated GSM should be, since some field experts frame it as affecting nearly all women eventually while the guidelines still call for treating diagnosed symptoms rather than treating everyone by default.
What the research shows, and which source each finding rests on
GSM covers dryness, burning, irritation, pain with sex, urgency, frequency, dysuria and recurrent UTIs, arising because the vagina, vulva, urethra and bladder are dense in estrogen and androgen receptors.
GSM is chronic and progressive and, unlike hot flashes, does not get better on its own without treatment.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Treat it as near-universal preventive care
Rachel Rubin and Kelly Casperson, field practice
GSM eventually affects the large majority of postmenopausal women, so field experts argue for thinking of vaginal hormone treatment as ongoing preventive care once menopause begins, not a therapy reserved only for women who already have severe symptoms.
Treat diagnosed symptoms, not everyone
AUA/SUFU/AUGS 2025 guideline
The guideline framework treats symptomatic, diagnosed GSM; no guideline currently recommends starting vaginal estrogen in every postmenopausal woman who has no symptoms.
What would settle it: Trials of starting treatment before symptoms appear, measured against outcomes like UTI, hospitalization and sepsis rates, would show whether prevention in asymptomatic women is warranted.
What is really going on here
- Could my urinary symptoms, urgency, frequency, burning, repeat UTIs, be hormonal?
- It's just vaginal dryness or part of aging - is that framing accurate?
Questions for your doctor
- Could my bladder symptoms and my vaginal symptoms be part of the same hormonal condition?
- Is this something that will improve on its own, or does it need ongoing treatment?
- What are all my treatment options, hormonal and non-hormonal?
- How common is this, and why wasn't it discussed with me sooner?
Questions with no answer yet
Does GSM's wide estimated prevalence range, 27 to 84 percent, reflect real variation across the populations studied, or mostly reflect how loosely or strictly the condition is defined study to study?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The position statement's own prevalence estimate spans a very wide range, and there is no study standardizing the case definition across the studies feeding that range, unlike the more careful definitional distinction made elsewhere in this knowledge base between a common symptom and a strictly diagnosed syndrome.
What would test it: A study applying one standardized case definition of GSM across multiple population samples to narrow the prevalence range.
If GSM is genuinely chronic and progressive without treatment, would starting treatment in every postmenopausal woman before symptoms even appear prevent more disease than waiting for symptoms, the way some field experts argue?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: There is a genuine, stated tension: some field experts argue for treating vaginal hormones as near-universal preventive care, while the guideline framework treats only diagnosed, symptomatic disease, and no trial has tested prophylactic initiation in asymptomatic women against outcomes like urinary infection, hospitalization, or sepsis.
What would test it: A trial of prophylactic vaginal hormone initiation in asymptomatic postmenopausal women, measured against urinary infection, hospitalization, and sepsis outcomes.
Is the low rate of women attributing their own symptoms to menopause, only 24 percent in one survey, mostly a knowledge gap, or does it also reflect that clinicians are not asking about these symptoms during routine visits?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The underlying survey documents the attribution gap and separately documents that most women never discussed symptoms with a clinician, without isolating how much of the gap is patient-side awareness versus clinician-side screening practice.
What would test it: A study directly measuring how often clinicians proactively screen for these symptoms during routine postmenopausal visits, compared with patient self-report rates.
Sources
- 1.The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause.AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, J Urol 2025;214(3):242-250 · Systematic review or guideline
- 2.The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The 2020 GSM position statement of The North American Menopause Society, Menopause 2020;27(9):976-992 · Systematic review or guideline
- 3.Case-Based Perspectives on the Management of Genitourinary Syndrome of Menopause.Cyriac J, Sood R. Case-Based Perspectives on the Management of GSM. Clin Pract 2026;16(3):60 · Systematic review or guideline
- 4.Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.Kingsberg SA, et al. REVIVE survey. J Sex Med 2013;10(7):1790-9 · Observational study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Is vaginal estrogen safe, and what happened to that scary warning label about stroke and cancer?
- Can I use vaginal estrogen if I've had breast cancer?
- I keep getting UTIs after menopause and keep getting put on antibiotics - can vaginal estrogen actually help?
- Sex has become painful since perimenopause - is this just something I have to live with?
- What is vaginal DHEA (prasterone) and how is it different from vaginal estrogen?
- What is ospemifene, the daily pill for painful sex, and how does it work?
- Back to topic: Vaginal, sexual and urinary health